We help families get clear insights into their incoming baby's health
Niptify is an accurate & safe test that analyses the most severe chromosomal diseases. A standard blood sample is all that’s required.
Why NIPTIFY?
EARLY
Available as early as ten weeks of pregnancy.
RELIABLE
The test qualifies for the strict requirements of ISO, CE-IVD, and EMQN.
INNOVATIVE
Focus Plus technology increases the reliability of the test compared to a regular NIPT test.
SAFE
A maternal blood sample is required for fetal DNA testing.
COMPREHENSIVE
NIPTIFY covers all the essential fetal chromosomal diseases, including microdeletions.
SECURE
NIPTIFY laboratory stores your genomic data according to strict regulations.
What does NIPTIFY provide?
Five most common chromosomal diseases
- Down syndrome
- DiGeorge syndrome (microdeletion)
- Edwards syndrome
- Turner syndrome
- Patau syndrome
Microdeletions and microduplications
18 carefully chosen genomic regions are involved in the analysis. The change in those regions may cause 20 chromosomal diseases altogether.
- Williams-Beuren syndrome
- 1p36 deletion syndrome
- Angelman and Prader-Willi syndrome
- Wolf-Hirschhorn syndrome
- Jacobsen syndrome
- Cri-du-chat or cat-cry syndrome
- Langer-Giedion syndrome
- And others. See the full list here
A large set of other conditions
NIPTIFY performs whole genome analysis and reports all clinically relevant trisomy or monosomy cases as incidental findings. For example:
- Trisomy 8
- Trisomy 9
- Trisomy 16
- Trisomy 22
Sex chromosome abnormalities
- Klinefelter syndrome (47,XXY)
- Jacobs syndrome (47,XYY)
- Trisomy X syndrome (47,XXX)
Mutations in mitochondrial DNA
Three mutations with applications in personalized medicine that help prevent hearing loss and deafness throughout a person's life. Read more HERE
- m1095T>C
- m1494C>T
- m1555A>G
Fetal sex
NIPTIFY determines the chromosomal sex of the fetus with 100% accuracy.
On average, there are five to ten microdeletions or microduplications affected kids per 10,000 newborns. NIPTIFY screens those related genomic regions to detect possible abnormalities in the early phase of pregnancy.
Choose the most suitable clinic for you to make an appointment with your obstetrician or midwife and perform the NIPTIFY test.
NIPTIFY Live Statistics
No Data Found
-Show More
High-Risk Proportions
No Data Found
Positive Predictive Value (PPV)
No Data Found
PPV – the percent that a high-risk NIPT result is confirmed in the fetus by amniocentesis, ultrasound, or after birth.
SCA – Sex Chromosome Aneuploidies like 45,X; 47,XXY; 47,XYY or 47,XXX.
MDS – Microdeletions/Duplications/Segmental changes.
RAT – Rare Autosomal Trisomies like trisomy 16, trisomy 22, trisomy 9 etc.
The accuracy and broad scope of the NIPTIFY leave only one puzzle for future parents - “What name should we pick for our baby?“
Kaarel Krjutškov, PhD
CEO, Principal Inventor of NIPTIFYWhy should you choose NIPTIFY for microdeletion detection?
The combined first-trimester screening test is unable to detect microdeletions. A DNA-based NIPT can only assess the risk of microdeletions already at the early phase of pregnancy. NIPTIFY Focus Plus test monitors DiGeorge’s syndrome and multiple microdeletions and microduplications.
DiGeorge’s syndrome (22q11) is a commonly occurring condition (1:1100 – 1:1500) that causes congenital heart abnormalities and mental retardation. This microdeletion develops spontaneously (de novo) and does not correlate with maternal age. Therefore, NIPTIFY testing is for all families to screen for the risk of the disease.
Why should you choose NIPTIFY for microdeletion detection?
The combined first-trimester screening test is unable to detect microdeletions. A DNA-based NIPT can only assess the risk of microdeletions already at the early phase of pregnancy. NIPTIFY Focus Plus test monitors DiGeorge’s syndrome and other microdeletions and microduplications.
DiGeorge’s syndrome (22q11) is a commonly occurring condition (1:1100 – 1:1500) that causes congenital heart abnormalities and mental retardation. This microdeletion develops spontaneously (de novo) and does not correlate with maternal age. Therefore, NIPTIFY testing is for all families to screen for the risk of the disease.
NIPTIFY is a CE-IVD-validated and registered in vitro medical diagnostic device. The test can be distributed all over European Union.
The NIPTIFY medical laboratory has ISO 15189:2012 accreditation and follows the highest standards.
NIPTIFY participates in the EMQN ja GenQA quality assurance test and has consistently earned the highest possible scores.
TECHNOLOGY
NIPTIFY uses the modern Focus Plus DNA sequencing technology, which enriches fetal DNA. As a result, NIPTIFY analysis 3.6 times more fetal origin DNA than a regular NIPT test, increasing the accuracy and sensitivity.
Focus Plus technology is designed for routine and reliable screening purposes. The need for re-testing is close to zero, and the test is suitable for overweight patients.